Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.

Journal Article (Journal Article)

BACKGROUND: Staphylococcus aureus bacteremia is a life-threatening infection and leading cause of infective endocarditis, with mortality rates of 15-50%. Treatment typically requires prolonged administration of parenteral therapy, itself associated with high costs and potential catheter-associated complications. Dalbavancin is a lipoglycopeptide with potent activity against Staphylococcus and a long half-life, making it an appealing potential therapy for S. aureus bacteremia without the need for durable central venous access. METHODS: DOTS is a phase 2b, multicenter, randomized, assessor-blinded, superiority, active-controlled, parallel-group trial. The trial will enroll 200 adults diagnosed with complicated S. aureus bacteremia, including definite or possible right-sided infective endocarditis, who have been treated with effective antibiotic therapy for at least 72 h (maximum 10 days) and with subsequent clearance of bacteremia prior to randomization to study treatment. Subjects will be randomized 1:1 to complete their antibiotic treatment course with either two doses of dalbavancin on days 1 and 8, or with a total of 4-8 weeks of standard intravenous antibiotic therapy. The primary objective is to compare the Desirability of Outcome Ranking (DOOR) at day 70 for patients randomized to dalbavancin versus standard of care. Key secondary endpoints include quality of life outcomes and pharmacokinetic analyses of dalbavancin. DISCUSSION: The DOTS trial will establish whether dalbavancin is superior to standard parenteral antibiotic therapy for the completion of treatment of complicated S. aureus bacteremia. TRIAL REGISTRATION: US National Institutes of Health ClinicalTrials.gov NCT04775953 . Registered on 1 March 2021.

Full Text

Duke Authors

Cited Authors

  • Turner, NA; Zaharoff, S; King, H; Evans, S; Hamasaki, T; Lodise, T; Ghazaryan, V; Beresnev, T; Riccobene, T; Patel, R; Doernberg, SB; Rappo, U; Fowler, VG; Holland, TL; Antibacterial Resistance Leadership Group (ARLG),

Published Date

  • May 16, 2022

Published In

Volume / Issue

  • 23 / 1

Start / End Page

  • 407 -

PubMed ID

  • 35578360

Pubmed Central ID

  • PMC9109297

Electronic International Standard Serial Number (EISSN)

  • 1745-6215

Digital Object Identifier (DOI)

  • 10.1186/s13063-022-06370-1


  • eng

Conference Location

  • England